Audio Conference: COVID-19's Impact on Lab Industry Testing Volumes and Dynamics - September Update

Blog Header - UBS June Call - Header

COVID-19's Impact on Lab Industry Testing Volumes and Dynamics - September Update 

UBS invites you to listen to the 1 hour audio conference recording, "COVID-19's Impact on Lab Industry Testing Volumes and Dynamics - September Update," to hear UBS Research Analysts and XIFIN Executives discuss the latest impacts in the short and long term, that COVID-19 has had on the laboratory and diagnostic testing industry.

Key Takeaways:

  • Learn how Laboratory and Diagnostic Testing Volumes have trended through the summer following state re-openings and further ramps in COVID testing capacity from a company that processes over $40bn of gross diagnostic claims annually
  • Learn how the COVID-19 outbreak has impacted diagnostic volumes, mix, and reimbursement for a variety of diagnostic providers (hospital, regional, reference, and national providers)
  • Understand the key factors that will impact COVID PCR and Serology testing volumes into the fall, including preferred platforms/instruments, overall market capacity, and new testing platforms such as recently approved antigen tests
  • Understand the financial conditions of the variety of diagnostic providers and how the COVID-19 outbreak has impacted might industry dynamics and payor behavior

UBS Speakers

  • Kevin Caliendo, UBS Healthcare Supply Chain & HCIT Senior Analyst
  • Dan Brennan, UBS Life Science Tools & Diagnostics Senior Analyst
  • ​Matt Taylor, CFA, UBS US Medical Supplies & Devices
  • Whit Mayo, UBS Healthcare Services and Managed Care Analyst

XIFIN Featured Speakers

Lâle White
Executive Chairman & CEO

Kyle Fetter
Executive Vice President & General Manager of Diagnostic Services

Details

UBS Genomics Summit
EVENT TYPE:
Webinar

RECORDING AVAILABLE